brain metastases

Related by string. Brain Metastases * brains . brainer . Brain . Brains . brained . BRAIN : traumatic brain injury . malignant brain tumor . cancerous brain tumor . suffered traumatic brain . battling brain tumor . traumatic brain injuries / Metastases : lymph node metastases . distant metastases . nodal metastases . occult metastases . bony metastases * brain metastases originating *

Related by context. All words. (Click for frequent words.) 71 liver metastases 69 preoperative chemotherapy 69 NSCLC 69 chemoradiation 68 metastatic disease 68 malignancies 68 tumor recurrence 67 adjuvant therapy 67 metastatic RCC 66 bone metastases 66 recurrent NSCLC 66 metastases 65 advanced NSCLC 65 locoregional recurrence 65 adjuvant radiation 65 metastatic cancer 65 neoadjuvant 65 heavily pretreated 65 neoadjuvant chemotherapy 65 renal cell carcinoma 65 metastatic colorectal cancer 65 relapsed ovarian cancer 65 metastatic renal cell carcinoma 64 HER2 positive breast cancer 64 HER2 positive 64 soft tissue sarcomas 64 renal tumors 64 carcinoid tumors 64 micrometastases 64 bone metastasis 64 locoregional 64 pCR 64 adjuvant chemotherapy 64 HER2 positive metastatic breast 64 chemoradiotherapy 64 basal cell carcinoma BCC 64 hepatocellular carcinoma 64 colorectal liver metastases 64 recurrent glioblastoma multiforme 64 lung metastases 64 IV NSCLC 64 mCRC patients 64 contralateral breast 63 castration resistant prostate cancer 63 hepatocellular carcinoma HCC 63 cetuximab 63 recurrent GBM 63 trastuzumab 63 dacarbazine 63 tumors 63 gemcitabine 63 temsirolimus 63 follicular lymphoma 63 distant metastases 63 pancreatic adenocarcinoma 63 KRAS mutations occur 63 heavily pretreated patients 63 tumor shrinkage 63 nonmelanoma skin cancers 63 cisplatin chemotherapy 63 lung metastasis 63 malignant pleural mesothelioma 63 metastatic breast cancer 63 acute leukemias 62 metachronous 62 neoadjuvant therapy 62 metastatic lesions 62 taxane therapy 62 distant metastasis 62 Adjuvant chemotherapy 62 acute myelogenous leukemia AML 62 indolent NHL 62 pegylated liposomal doxorubicin 62 lymphomas 62 medically inoperable 62 hepatic metastases 62 vandetanib 62 bortezomib 62 contralateral breast cancer 62 HER2 positive cancers 62 liver metastasis 62 neuroendocrine tumors 62 temozolomide 62 epithelial tumors 62 superficial bladder cancer 62 thromboembolic events 62 solid tumors 62 carcinomas 62 ependymoma 62 carboplatin paclitaxel 62 unresectable 62 nonmetastatic 62 axitinib 61 SCCHN 61 adenocarcinomas 61 KRAS wild 61 non squamous NSCLC 61 plus dexamethasone 61 EBRT 61 MGd 61 hepatocellular cancer 61 cytoreduction 61 chemotherapy regimens 61 medullary thyroid cancer 61 5FU 61 gastric cancer 61 metastatic melanoma 61 metastatic prostate cancer 61 tumor resection 61 neoadjuvant treatment 61 HRPC 61 endometrial carcinoma 61 vinorelbine 61 pulmonary metastases 61 chemoradiation therapy 61 cranial radiation 61 chlorambucil 61 FOLFOX 61 paroxysmal AF 61 gemcitabine carboplatin 61 cytotoxic chemotherapy 61 XELOX 61 sorafenib 61 Tavocept 61 advanced adenomas 61 carcinoma 61 stage IIIB 61 dasatinib 61 lymph node metastases 61 biochemical recurrence 61 trabectedin 61 endometrial hyperplasia 61 histologies 61 recurrent glioblastoma 61 metastatic lung cancer 61 TACE 61 carcinoid 61 fallopian tube carcinoma 61 WBRT 61 operable breast cancer 61 bevacizumab 61 5-FU/LV 61 metastatic bladder 61 chemotherapeutic regimens 61 sunitinib 61 platinum refractory 61 gastric cancers 60 malignant neoplasms 60 cytoreductive surgery 60 Doxil ® 60 chronic lymphocytic leukemia CLL 60 metastatic GIST 60 HER2 negative 60 low dose cytarabine 60 glioblastoma 60 radical nephrectomy 60 postoperative chemotherapy 60 unresectable stage 60 FOLFIRI 60 nonsmall cell lung cancer 60 renal cell carcinomas 60 cell carcinoma 60 pancreatic cancers 60 differentiated thyroid 60 mRCC 60 prognostic variables 60 topotecan 60 endometrial cancers 60 GISTs 60 nephrectomy 60 chemoembolization 60 leukemia AML 60 refractory NSCLC 60 docetaxel chemotherapy 60 gastrointestinal cancers 60 adecatumumab 60 surgical debulking 60 pancreatic NET 60 azacitidine 60 hormone refractory prostate cancer 60 Amrubicin 60 sorafenib Nexavar ® 60 DLBCL 60 peritoneal carcinomatosis 60 PSADT 60 cilengitide 60 lymphadenectomy 60 sarcomas 60 DMARD 60 bendamustine 60 dacarbazine DTIC 60 cancers 60 astrocytomas 60 prostate adenocarcinoma 60 nab paclitaxel 60 myocardial infarctions 60 chemotherapy regimen 60 refractory multiple myeloma 60 adenomas 60 metastatic malignant melanoma 60 interferon alfa 60 definite stent thrombosis 60 prostate cancer CaP 60 docetaxel 60 metastatic 60 axillary lymph nodes 59 relapsing remitting 59 curative resection 59 FOLFOX4 59 free survival PFS 59 androgen deprivation 59 complete remissions 59 grade gliomas 59 thymoma 59 lymph node involvement 59 Xcytrin 59 relapsed MM 59 recurrent VTE 59 metastatic bone 59 squamous histology 59 resectable 59 gastrointestinal stromal tumors 59 bladder cancers 59 malignant lesions 59 axillary node dissection 59 breast carcinoma 59 gefitinib 59 adenocarcinoma 59 cediranib 59 neoplasms 59 cardiac dysfunction 59 KRAS mutant tumors 59 CR nPR 59 antiplatelet therapy 59 MALT lymphoma 59 relapsed refractory multiple myeloma 59 radiochemotherapy 59 Bezielle 59 gemcitabine chemotherapy 59 mitoxantrone 59 lung tumors 59 adenoma 59 gemcitabine Gemzar 59 carboplatin 59 atypical hyperplasia 59 anthracyclines 59 refractory CTCL 59 relapsing multiple sclerosis 59 basal cell carcinomas 59 systemic lupus erythematosus SLE 59 hypercalcemia 59 CMV disease 59 liposomal doxorubicin 59 debulking surgery 59 chronic GVHD 59 GnRH agonists 59 relapsed AML 59 anti leukemic 59 advanced adenoma 59 standard chemotherapy regimens 59 neuroblastomas 59 Metastatic 59 cancer mCRC 59 Flu Cy 59 metastatic tumors 59 squamous cell carcinoma SCC 59 mycophenolate mofetil 59 glioblastoma multiforme GBM 59 neoadjuvant radiation 59 PXD# 59 disease progression 59 adjuvant radiotherapy 59 clinically localized prostate 59 prostate cancer CRPC 59 TORISEL 59 evaluable patients 59 acute ischemic stroke 59 irinotecan chemotherapy 59 Wilms tumors 59 EOquin TM 59 ELOXATIN 59 Hodgkin lymphoma HL 59 biliary tract cancer 59 IMGN# 59 Tamibarotene 59 relapsed SCLC 59 estramustine 59 cell lung cancer 59 Fludara 59 tamoxifen therapy 59 gastric adenocarcinoma 59 EGFR mutations 58 anti angiogenic therapy 58 pancreatic carcinoma 58 Genasense ® 58 neurologic progression 58 plus gemcitabine 58 epirubicin 58 ipsilateral stroke 58 Folfox 58 hematologic toxicity 58 thrombotic events 58 PCNSL 58 HSCT 58 anti TNF 58 graft dysfunction 58 H. pylori eradication 58 neoplasm 58 KRAS status 58 Thalomid ® 58 RRMS patients 58 OPAXIO 58 infusional 5-FU/LV 58 venous thromboembolic events 58 metastatic kidney 58 mesotheliomas 58 TEMODAL 58 recurrent ovarian cancer 58 Toxicities 58 papillary thyroid cancer 58 Halaven 58 sentinel lymph node biopsy 58 metastatic gastric 58 bevacizumab Avastin ® 58 afatinib 58 gastrointestinal stromal tumor GIST 58 SLNB 58 INCB# [003] 58 radiation therapy WBRT 58 mTOR inhibitors 58 axillary dissection 58 prognostic factors 58 peritoneal cancer 58 TREANDA 58 panobinostat 58 gastroesophageal junction 58 glioblastomas 58 remission induction 58 refractory metastatic colorectal cancer 58 malignant growths 58 cisplatin 58 trans retinoic acid 58 seminoma 58 histologic subtype 58 metastatic HRPC 58 extracranial 58 osteosarcomas 58 hematologic malignancies 58 virologic failure 58 metastatic CRC 58 allogeneic stem cell 58 carcinoid tumor 58 imatinib Gleevec 58 stage IIIA 58 resistant ovarian cancer 58 Cytoxan 58 nonischemic 58 ischemic cardiomyopathy 58 cabazitaxel 58 breast cancer recurrence 58 adenomatous polyps 58 hormone receptor positive 58 lobular cancer 58 ixabepilone 58 Torisel 58 tumor 58 androgen suppression 58 YONDELIS 58 astrocytoma 58 invasive carcinoma 58 lapatinib 58 nonfatal MI 58 pomalidomide 58 ELACYT 58 lymphocytosis 58 bleomycin 58 imetelstat 58 capecitabine 58 enzastaurin 58 posaconazole 58 erlotinib 58 pazopanib 58 recurrent malignant glioma 58 HCV infection 58 pheochromocytoma 58 rFVIIa 58 liver resection 58 TNF blocker therapy 58 MGUS 58 mCRC 58 geographic atrophy 58 severe neutropenia 58 decitabine 58 breast carcinomas 58 EFAPROXYN 58 colorectal tumors 58 antiangiogenic therapy 58 erlotinib Tarceva ® 58 hepatectomy 58 underwent resection 58 tolvaptan 58 grade glioma 58 relapsing MS 58 uterine cancers 58 lupus nephritis 58 malignancy 57 ovarian carcinoma 57 fluorouracil 57 anastrozole 57 refractory AML 57 cystectomy 57 thrombotic complications 57 IV melanoma 57 external beam radiotherapy 57 sunitinib malate 57 palliation 57 cervical lymph nodes 57 relapsing remitting MS 57 serous ovarian cancer 57 recurrent metastatic 57 invasive breast cancer 57 stage IIIb IV 57 COPAXONE R 57 relapsing remitting multiple sclerosis 57 MACCE 57 breast irradiation 57 proliferative diabetic retinopathy 57 papillary 57 systemic ALCL 57 Surgical resection 57 DMARDs 57 multiple myeloma 57 aflibercept 57 cranial irradiation 57 surrogate endpoint 57 skeletal metastases 57 Hepatocellular Carcinoma HCC 57 esophageal cancers 57 premalignant 57 CaP 57 epithelial ovarian 57 neoplasia 57 NMIBC 57 interferon alfa 2a 57 hypoparathyroidism 57 pericardial effusion 57 androgen ablation 57 FluCAM 57 meningiomas 57 intravenous bisphosphonates 57 dosage regimens 57 B CLL 57 chronic HBV infection 57 Metastatic breast cancer 57 leukemia ALL 57 intestinal metaplasia 57 pertuzumab 57 lobular carcinoma 57 APTIVUS r 57 myelofibrosis MF 57 anthracycline taxane 57 pneumonectomy 57 ALND 57 completely resected 57 K ras mutations 57 oral clodronate 57 lesions 57 allogeneic HSCT 57 iniparib 57 lung cancers 57 lymph node removal 57 oblimersen 57 AA amyloidosis 57 lymphoma CTCL 57 CYT# potent vascular disrupting 57 anterior uveitis 57 lymph node dissection 57 tumor histology 57 medulloblastomas 57 sarcomatoid 57 cutaneous melanoma 57 receptor tyrosine kinase inhibitor 57 breast tumors 57 refractory CLL 57 metastatic colon cancer 57 localized prostate cancer 57 cardiotoxicity 57 zalutumumab 57 gastrointestinal stromal tumor 57 fluoropyrimidine 57 medulloblastoma 57 sarcoma 57 alkylating agent 57 grade cervical intraepithelial 57 nimotuzumab 57 carcinoids 57 cardiac toxicity 57 chemotherapy docetaxel 57 vismodegib 57 recurrent prostate cancer 57 ventricular dysfunction 57 pleural mesothelioma 57 paraganglioma 57 chemotherapies 57 mapatumumab 57 TNF antagonist 57 infarcts 57 trastuzumab Herceptin ® 57 reinfarction 57 squamous cell carcinoma 57 taxane chemotherapy 57 Glioblastoma 57 anthracycline chemotherapy 57 VaD 57 Metastatic Colorectal Cancer 57 phase IIb clinical 57 colorectal adenomas 57 invasive fungal infection 57 Response Evaluation Criteria 57 PAOD 57 Xelox 57 advanced hepatocellular carcinoma 57 Median survival 57 soft tissue sarcoma 57 palliative radiotherapy 57 abiraterone acetate 57 papillary renal cell carcinoma 57 tumor progression 57 acute myeloid leukemia AML 57 squamous cell 57 metastatic renal cell 57 symptomatic VTE 57 colectomy 57 basal cell cancers 57 cisplatin vinorelbine 57 myeloproliferative diseases 57 FOLFOX regimen 57 thyroid nodules 57 placebo controlled clinical 57 HNSCC 57 paclitaxel Taxol ® 57 pelvic lymphadenectomy 57 extrapleural pneumonectomy 57 TTF Therapy 57 mycosis fungoides 57 CA4P 57 nasopharyngeal carcinoma 57 GvHD 57 Irinotecan 57 imatinib therapy 57 biologic therapy 57 tumor regression 56 essential thrombocythemia 56 colorectal carcinoma 56 FOLFIRI alone 56 Cotara 56 invasive aspergillosis 56 hormonal therapy 56 CIMZIA ™ 56 antitumor effect 56 premalignant lesions 56 invasive candidiasis 56 EGFr 56 pemetrexed 56 prior chemotherapy regimens 56 perioperative complications 56 Bortezomib 56 postoperative radiotherapy 56 SUTENT 56 neuroendocrine cancers 56 ovarian lung 56 radiation therapy SBRT 56 IV malignant melanoma 56 HIF PHI 56 stage IIIB IV 56 paclitaxel eluting stents 56 xenograft models 56 Chronic lymphocytic leukemia 56 hormone receptor negative 56 ductal cancer 56 EGFR inhibitors 56 recurrent DVT 56 5 FU 56 radiotherapy RT 56 carotid stenosis 56 invasive bladder 56 invasive ductal carcinoma 56 BRAF inhibitor 56 octreotide LAR 56 TEAEs 56 precursor lesions 56 Vectibix 56 exemestane 56 idarubicin 56 colorectal cancers 56 paclitaxel carboplatin 56 esophagectomy 56 TRISENOX 56 hepatorenal syndrome 56 Glioblastoma Multiforme 56 metastatic colorectal 56 myelodysplastic syndromes MDS 56 chemotherapy 56 myelofibrosis 56 SUVmax 56 Xanafide 56 eribulin 56 cytotoxic therapy 56 AP# [003] 56 bevacizumab Avastin 56 Thal Dex 56 osteosarcoma 56 radiation therapy 56 sorafenib Nexavar 56 recurrent glioblastoma multiforme GBM 56 adrenalectomy 56 cutaneous squamous cell carcinoma 56 IV metastatic melanoma 56 lung fibrosis 56 5-fluorouracil/leucovorin 56 adenomatous 56 histological subtypes 56 meningioma 56 perifosine 56 solar keratoses 56 tumoral 56 vorinostat 56 alemtuzumab treated 56 histologically confirmed 56 trans retinoic acid ATRA 56 Allovectin 7 ® 56 ALA PDT 56 metastatic pancreatic 56 bronchogenic carcinoma 56 metastasis 56 CLL SLL 56 ErbB2 positive 56 fallopian tube cancers 56 pulmonary nodules 56 prostate cancers 56 DIPG 56 BRCA mutation carriers 56 esophageal tumors 56 Glioblastoma Multiforme GBM 56 histologically proven 56 Azixa 56 daunorubicin 56 melphalan prednisone 56 diagnosed multiple myeloma 56 malignant lymphoma 56 partial nephrectomy 56 gastric carcinoma 56 VEGF inhibitors 56 concurrent chemoradiation 56 thalidomide Thalomid 56 Proxinium TM 56 hematopoietic cancers 56 CTEPH 56 postoperative atrial fibrillation 56 parathyroid 56 imatinib 56 adrenocortical cancer 56 Imprime PGG 56 small lymphocytic lymphoma 56 liver transplant recipients 56 indolent lymphomas 56 nodal metastases 56 therapeutic regimens 56 Chronic Lymphocytic Leukemia CLL 56 dose cohorts 56 IL# PE#QQR 56 infarct size 56 AEG# 56 subependymal giant cell 56 placebo dexamethasone 56 HER2 positive tumors 56 hepatocellular carcinomas 56 breast conserving 56 anthracycline 56 revascularization procedures 56 mucinous 56 depsipeptide 56 refractory angina 56 T2 lesions 56 cinacalcet 56 HbF 56 renal carcinoma 56 rituximab 56 bosentan 56 recurrent venous thromboembolism 56 resected 56 CCyR 56 sirolimus 56 tyrosine kinase inhibitors 56 pituitary adenomas 56 Bevacizumab 56 endometrial cancer 56 breast cancers 56 chemotherapeutic agent 56 breast cancer subtypes 56 colorectal adenoma 56 epithelial ovarian cancer 56 adjuvant cisplatin 56 zoledronic acid 56 HER2 + 56 node metastases 56 paclitaxel cisplatin 56 Neuradiab 56 atherosclerotic disease 56 docetaxel Taxotere ® 56 relapsed Hodgkin lymphoma 56 pancreatic neuroendocrine tumors 56 Genasense 56 hypoperfusion 56 chemotherapeutic agents 56 adriamycin 56 oral ridaforolimus 56 anti angiogenic agents 56 pancreatic tumors 56 hormonal therapies 56 prostate cancer PCa 56 calcineurin inhibitors 56 Cladribine Tablets 56 sorafenib tablets 56 goserelin 56 follicular lymphomas 56 capecitabine Xeloda R 56 Gliadel Wafer 56 ADPKD 56 DMARD therapy 56 ipsilateral breast 56 leukemia CLL 56 dacarbazine chemotherapy 56 nonmelanoma skin cancer 56 HGPIN 56 acute GvHD 56 ABVD 56 calcineurin inhibitor 56 prospectively defined 56 urothelial bladder cancer 56 opioid induced constipation OIC 56 nonresponders 56 INC# 56 letrozole 56 KRAS mutations 55 Ceflatonin 55 Tyrima 55 oral Hycamtin 55 myeloablative 55 sustained virologic response 55 IRX 2 55 stereotactic radiotherapy 55 CLL 55 riociguat 55 colorectal cancer CRC 55 Metastatic colorectal cancer 55 idraparinux 55 olaparib 55 nonalcoholic steatohepatitis NASH 55 renal insufficiency 55 pancreatic prostate 55 cerebral infarction 55 postoperative AF 55 resected pancreatic cancer 55 glufosfamide 55 leukoencephalopathy 55 mg kg dose 55 cell lymphomas 55 arterial thrombosis 55 Kaplan Meier analysis 55 brain tumors 55 docetaxel Taxotere 55 biochemical relapse 55 alveolar rhabdomyosarcoma 55 axillary node 55 Acute Coronary Syndromes ACS 55 standard chemotherapy regimen 55 irinotecan 55 Glioma 55 CMV infection 55 histologically 55 Pemetrexed 55 timepoints 55 PROSTVAC TM 55 gemcitabine cisplatin 55 recurrent glioma 55 familial ALS 55 malignant pheochromocytoma 55 anticancer therapy 55 FDG PET 55 papillary RCC 55 adjuvant therapies 55 allogeneic bone marrow 55 metastatic malignant 55 histologic 55 splenectomized patients 55 tesmilifene 55 curative therapy 55 metastatic liver 55 Cloretazine 55 BR.# 55 Brain metastases 55 histological subtype 55 cervical carcinoma 55 uveal melanoma 55 EGFR mutation 55 generalized seizures 55 metastatic cancers 55 micrometastasis 55 hamartomas 55 CANCIDAS 55 ADVEXIN 55 iniparib BSI 55 follicular lymphoma FL 55 Severe Primary IGFD 55 VIDAZA 55 non squamous 55 transaminase levels 55 R0 resection 55 squamous cell histology 55 azathioprine 55 glioblastoma tumors 55 Trastuzumab 55 Barrett esophagus BE 55 pegylated interferon alfa 2b 55 situ LCIS 55 myocardial ischemia 55 Lenalidomide 55 median PFS 55 candidemia 55 prostate cancer HRPC 55 Xeloda 55 ischemic lesions 55 natalizumab 55 Wilms tumor 55 coronary lesions 55 taxanes 55 ALT flares 55 dexamethasone 55 EXJADE 55 myelosuppression 55 renal dysfunction 55 KRAS mutation 55 parathyroidectomy 55 visceral metastases 55 non metastatic osteosarcoma 55 malignant tumors 55 FOLFOX6 55 melanoma tumors 55 talabostat 55 dasatinib Sprycel 55 sleeve lobectomy 55 thyroid cancers 55 PCa 55 Voreloxin 55 figitumumab 55 relapsed multiple myeloma 55 tocilizumab 55 tumor lysis syndrome 55 cerebral vasospasm 55 tumor subtypes 55 MYCN amplification 55 lenalidomide dexamethasone 55 cintredekin besudotox 55 Cutaneous T 55 lung carcinomas 55 levodopa therapy 55 neovascular AMD 55 BRAF mutation 55 ALCL 55 squamous cell cancers 55 GIST 55 rebleeding 55 locoregional disease 55 lymphoma 55 perioperative mortality 55 cholangiocarcinoma 55 panitumumab 55 severe exacerbations 55 chemotherapy cisplatin 55 prophylactic cranial irradiation 55 choroidal neovascularization CNV 55 antitumor activity 55 regorafenib 55 advanced unresectable 55 myelofibrosis polycythemia vera 55 rectal cancers 55 Azedra 55 amrubicin 55 patients evaluable 55 FOLOTYN 55 dirucotide 55 Taxotere ® 55 Zevalin consolidation 55 schwannomas 55 GIST tumors 55 fibrosis 55 melanoma 55 systemic lupus erythematosus 55 juvenile idiopathic arthritis 55 unresectable tumors 55 endocrine therapy 55 anaplastic 55 gastrectomy 55 CR CRu 55 gastrointestinal stromal tumors GIST 55 HBeAg negative 55 gadolinium enhanced 55 salpingo oophorectomy 55 nasopharyngeal cancer 55 upper gastrointestinal bleeding 55 diabetic nephropathy 55 invasive ductal 55 AGILECT R 55 teriflunomide 55 fludarabine 55 BRIM2 55 interferon therapy 55 prostate cancer AIPC 55 renal toxicity 55 nonrandomized 55 EGFR expressing mCRC 55 EGFR mutation positive 55 hyperoxaluria 55 prostate carcinoma 55 atypia 55 Alpharadin 55 liposarcoma 55 multiple myeloma MM 55 BAY #-# 55 radioiodine therapy 55 vertebral fracture 55 lymphoid malignancies 55 underwent surgical resection 55 clinicopathological features 55 eplerenone 55 squamous cell lung cancer 55 corticosteroid therapy 55 white matter hyperintensities 55 dose cytarabine 55 carcinoma HCC 55 ribavirin therapy 55 pamidronate 55 thromboembolic 55 alvespimycin 55 adenoma recurrence 55 evaluable 55 acute GVHD 55 spinal metastases 55 peg IFN 55 colorectal adenocarcinoma 55 fluvastatin 55 myeloproliferative neoplasms 55 T1a 55 Carcinoma 55 SHPT 55 alteplase 55 paclitaxel 55 Sezary syndrome 55 intracranial tumors 55 situ CIS 55 lymph node metastasis 55 BRCA deficient 55 tumors GIST 55 cardiogenic shock 55 EGFR TKI 55 myelodysplastic syndromes 55 Hematologic 55 partial remissions 55 gefitinib Iressa 55 fibrotic disease 55 relapsing remitting MS RRMS 55 rectal carcinoma 55 aHUS 55 synovial sarcoma 55 MabCampath 55 myelodysplastic syndrome MDS 55 velafermin 55 PASI scores 54 Cell Lung Cancer 54 metastatic pancreatic cancer 54 seminomas 54 Fludara ® 54 idiopathic pulmonary fibrosis IPF 54 androgen independent 54 ASCT 54 chronic angina 54 thrombocytopenic patients 54 lymphocytic leukemia 54 cryptogenic stroke 54 durable remissions 54 TYKERB 54 diagnosed GBM 54 bowel resection 54 ependymomas 54 androgen deprivation therapy 54 bladder carcinoma 54 dosing cohort 54 HGS#

Back to home page